Targeting hypoxia in cancer therapy (Q29615491)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Targeting hypoxia in cancer therapy (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21606941

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

William R Wilson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21606941

1 February 2020

language of work or name

1 reference

30 April 2017

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

published in

Nature Reviews Cancer

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21606941

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

11

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21606941

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

6

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21606941

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

393-410

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21606941

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 February 2020

cites work

1 reference

Structural adaptation and heterogeneity of normal and tumor microvascular networks

31 March 2020

1 reference

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

31 March 2020

1 reference

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

31 March 2020

1 reference

Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance

31 March 2020

1 reference

The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5.

31 March 2020

1 reference

Regulation of cancer cell metabolism

31 March 2020

1 reference

Hypoxia, clonal selection, and the role of HIF-1 in tumor progression

31 March 2020

1 reference

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

31 March 2020

1 reference

Cancer stem cells, hypoxia and metastasis

31 March 2020

1 reference

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

31 March 2020

1 reference

Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer

31 March 2020

1 reference

Hypoxic tumors and their effect on immune cells and cancer therapy

31 March 2020

1 reference

Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing

31 March 2020

1 reference

Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

31 March 2020

1 reference

Detection and characterization of tumor hypoxia using pO2 histography

31 March 2020

1 reference

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

31 March 2020

1 reference

Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis

31 March 2020

1 reference

Cure of Mice bearing Advanced Plasma Cell Tumours with Aniline Mustard : the Relationship between Glucuronidase Activity and Tumour Sensitivity

31 March 2020

1 reference

The role of catalytic superoxide formation in the O2 inhibition of nitroreductase

31 March 2020

1 reference

Hypoxic cell sensitisers in radiotherapy

31 March 2020

1 reference

Chemical radiosensitizers for use in radiotherapy

31 March 2020

1 reference

MITOMYCIN C: CHEMICAL AND BIOLOGICAL STUDIES ON ALKYLATION

31 March 2020

1 reference

MITOMYCINS AND PORFIROMYCIN: CHEMICAL MECHANISM OF ACTIVATION AND CROSS-LINKING OF DNA.

31 March 2020

1 reference

Potential bioreductive alkylating agents. 1. Benzoquinone derivatives

31 March 2020

1 reference

Measurement of Electrode Potentials in Living and Dead Tissues

31 March 2020

1 reference

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

31 March 2020

1 reference

DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).

31 March 2020

1 reference

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase

31 March 2020

1 reference

Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent

31 March 2020

1 reference

Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide

31 March 2020

1 reference

Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards

31 March 2020

1 reference

Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator

31 March 2020

1 reference

A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs

31 March 2020

1 reference

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

31 March 2020

1 reference

Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia

31 March 2020

1 reference

Combining bioreductive drugs and radiation for the treatment of solid tumors.

31 March 2020

1 reference

Targeting tumors with hypoxia-activated cytotoxins

31 March 2020

1 reference

Design of anticancer prodrugs for reductive activation.

31 March 2020

1 reference

Selective Treatment of Hypoxic Tumor Cells In Vivo: Phosphate Pre‐Prodrugs of Nitro Analogues of the Duocarmycins

31 March 2020

1 reference

Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells

31 March 2020

1 reference

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.

31 March 2020

1 reference

Maintaining genome stability at the replication fork

31 March 2020

1 reference

Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug

31 March 2020

1 reference

Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.

31 March 2020

1 reference

A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia

31 March 2020

1 reference

Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase

31 March 2020

1 reference

Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential

31 March 2020

1 reference

The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)

31 March 2020

1 reference

NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs

31 March 2020

1 reference

Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1)

31 March 2020

1 reference

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3

31 March 2020

1 reference

In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity

31 March 2020

1 reference

Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues

31 March 2020

1 reference

Nuclear factor Nrf2 and antioxidant response element regulate NRH:quinone oxidoreductase 2 (NQO2) gene expression and antioxidant induction

31 March 2020

1 reference

Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling comp

31 March 2020

1 reference

Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway

31 March 2020

1 reference

Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.

31 March 2020

1 reference

The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.

31 March 2020

1 reference

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

31 March 2020

1 reference

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors

31 March 2020

1 reference

Drug penetration in solid tumours

31 March 2020

1 reference

Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice

31 March 2020

1 reference

Evaluation of bioreductive drugs in multicell spheroids

31 March 2020

1 reference

Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.

31 March 2020

1 reference

Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.

31 March 2020

1 reference

Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs

31 March 2020

1 reference

Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity

31 March 2020

1 reference

Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors

31 March 2020

1 reference

Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs

31 March 2020

1 reference

Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771

31 March 2020

1 reference

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

31 March 2020

1 reference

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine

31 March 2020

1 reference

DNA repair pathways as targets for cancer therapy

31 March 2020

1 reference

2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone

31 March 2020

1 reference

Bioreductively-activated prodrugs for targeting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives

31 March 2020

1 reference

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4

31 March 2020

1 reference

Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours

31 March 2020

1 reference

Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine

31 March 2020

1 reference

Targeting HIF-1 for cancer therapy

31 March 2020

1 reference

Targeting the hypoxia-inducible factor (HIF) pathway in cancer.

31 March 2020

1 reference

Hypoxia signalling through mTOR and the unfolded protein response in cancer

31 March 2020

1 reference

Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies

31 March 2020

1 reference

Evaluation of HIF-1 inhibitors as anticancer agents

31 March 2020

1 reference

HIF-1 as a target for drug development

31 March 2020

1 reference

Targeting hypoxia cell signaling for cancer therapy

31 March 2020

1 reference

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

31 March 2020

1 reference

The HIF-1-active microenvironment: an environmental target for cancer therapy

31 March 2020

1 reference

Regulation of autophagy through multiple independent hypoxic signaling pathways.

31 March 2020

1 reference

The FAD- and O(2)-dependent reaction cycle of Ero1-mediated oxidative protein folding in the endoplasmic reticulum

31 March 2020

1 reference

Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor

31 March 2020

1 reference

ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth

31 March 2020

1 reference

XBP1 is essential for survival under hypoxic conditions and is required for tumor growth.

31 March 2020

1 reference

Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth.

31 March 2020

1 reference

Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma

31 March 2020

1 reference

Potent and Selective Inhibitors of the Inositol-requiring Enzyme 1 Endoribonuclease

31 March 2020

1 reference

Structure of the Dual Enzyme Ire1 Reveals the Basis for Catalysis and Regulation in Nonconventional RNA Splicing

31 March 2020

1 reference

Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.

31 March 2020

1 reference

"Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways

31 March 2020

1 reference

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

31 March 2020

1 reference

Hypoxia-induced energy stress regulates mRNA translation and cell growth

31 March 2020

1 reference

Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb

31 March 2020

1 reference

Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis

31 March 2020

1 reference

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

31 March 2020

1 reference

Regulation of autophagy by ATF4 in response to severe hypoxia.

31 March 2020

1 reference

HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms.

31 March 2020

1 reference

The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes

31 March 2020

1 reference

Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells

31 March 2020

1 reference

Preferential cytotoxicity of 5-thio-D-glucose against hypoxic tumor cells

31 March 2020

1 reference

Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells".

31 March 2020

1 reference

Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.

31 March 2020

1 reference

A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death

31 March 2020

1 reference

AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10

31 March 2020

1 reference

Monocarboxylate transporter MCT1 is a target for immunosuppression

31 March 2020

1 reference

Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer

31 March 2020

1 reference

The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism.

31 March 2020

1 reference

Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.

31 March 2020

1 reference

Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.

31 March 2020

1 reference

Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response

31 March 2020

1 reference

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

31 March 2020

1 reference

Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression

31 March 2020

1 reference

Targeting Hypoxic Cells through the DNA Damage Response

31 March 2020

1 reference

Tumor hypoxia as a modifier of DNA strand break and cross-link repair.

31 March 2020

1 reference

Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest

31 March 2020

1 reference

Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability

31 March 2020

1 reference

Ribonucleotide reductases

31 March 2020

1 reference

Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation

31 March 2020

1 reference

ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation

31 March 2020

1 reference

CHK2-dependent phosphorylation of BRCA1 in hypoxia

31 March 2020

1 reference

EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling

31 March 2020

1 reference

In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection.

31 March 2020

1 reference

Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells

31 March 2020

1 reference

Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance

31 March 2020

1 reference

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

31 March 2020

1 reference

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis

31 March 2020

1 reference

Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia

31 March 2020

1 reference

Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia

31 March 2020

1 reference

Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study

31 March 2020

1 reference

Molecular imaging of hypoxia with radiolabelled agents

31 March 2020

1 reference

The experimental development of bioreductive drugs and their role in cancer therapy.

31 March 2020

1 reference

Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies

31 March 2020

1 reference

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

31 March 2020

1 reference

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

31 March 2020

1 reference

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

31 March 2020

1 reference

Network medicine: a network-based approach to human disease

31 March 2020

1 reference

Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules

31 March 2020

1 reference

Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro

31 March 2020

1 reference

Nitric oxide synthase activity in human breast cancer

31 March 2020

1 reference

Inducible nitric oxide synthase with transitional cell carcinoma of the bladder

31 March 2020

1 reference

Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies

31 March 2020

1 reference

A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter

31 March 2020

1 reference

17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.

31 March 2020

1 reference

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

31 March 2020

1 reference

Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases

31 March 2020

1 reference

Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer

31 March 2020

1 reference

Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure

31 March 2020

1 reference

Aerobic reduction of 5-nitro-2-furaldehyde semicarbazone by rat liver xanthine dehydrogenase

31 March 2020

1 reference

Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours

31 March 2020

1 reference

PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.

31 March 2020

1 reference

18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.

31 March 2020

1 reference

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation O

31 March 2020

1 reference

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

31 March 2020

1 reference

Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: implications for the mechanism of HIF-1alpha stabilization under moderate hypoxia

31 March 2020

1 reference

The unfolded protein response and integrated stress response to anoxia

31 March 2020

1 reference

Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents

31 March 2020

1 reference

12 December 2020

Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.

1 reference

12 December 2020

Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas

1 reference

12 December 2020

Multimodality imaging of hypoxia in preclinical settings

1 reference

12 December 2020

A general mechanism for microsomal activation of quinone anticancer agents to free radicals

1 reference

12 December 2020

Nitroaromatic betulin derivatives as redox cycling agents

1 reference

12 December 2020

Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1

1 reference

12 December 2020

Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells

1 reference

12 December 2020

Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells

1 reference

12 December 2020

Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.

1 reference

12 December 2020

Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

1 reference

12 December 2020

Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice

1 reference

12 December 2020

Reductive activation of mitomycin C by NADH:cytochrome b5 reductase.

1 reference

12 December 2020

Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis

1 reference

12 December 2020

Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity

1 reference

12 December 2020

Oxygen-mediated endocytosis in cancer

1 reference

12 December 2020

Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy

1 reference

12 December 2020

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21606941

Identifiers

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21606941%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 February 2020

1041261140

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21606941

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017